Clinical Pharmacology of Oxymorphone
by
Smith HS.
Anesthesiology and Academic Director of Pain Management,
Albany Medical College,
Department of Anesthesiology,
Albany, New York, USA.
Pain Med. 2009 Apr;10(s1Oxymorphone):S3-S10.

ABSTRACT

Oxymorphone (14-hydroxydihydromorphinone) is primarily a potent mu-opioid receptor agonist with oral immediate-release (IR) and extended-release (ER) formulations approved in the United States in 2006. The oral oxymorphone formulations are roughly three times more potent than oral morphine. It is more lipophilic than morphine and, thus, may more easily cross the blood-brain barrier because it differs from morphine having a ketone-group substituent at the C-6 position. Oxymorphone IR is indicated for the relief of moderate-to severe pain, while oxymorphone ER is indicated for persistent pain. Initial doses (opioid-naïve) are 10-20 mg every 4-6 hours (IR) and 5 mg every 12 hours (ER). Oxymorphone was found not to have any clinically significant cytochrome (CYP)3A4, CPY2C9, or CYP2D6 interactions, thus limiting its potential for causing some of the more common drug-drug interactions via the CYP450 system. The common adverse effects of oxymorphone are consistent with those commonly seen with other opioid, including nausea/vomiting, constipation, pruritis, pyrexia, somnolence, and sedation.

Pain
Opioids
Arousal
Fentanyl
Tramadol
Tolerance
Nociceptin
Remifentanil
Endomorphins
P-glycoprotein
NMDA anatagonists
Tramadol versus oxycodone
Oxymorphone (Numorphan): structure
Use of oxycodone and oxymorphone to treat major depression

Refs
and further reading

HOME
HedWeb
Nootropics
cocaine.wiki
Future Opioids
BLTC Research
MDMA/Ecstasy
Superhapiness?
Utopian Surgery?
The Abolitionist Project
The Hedonistic Imperative
The Reproductive Revolution
Critique of Huxley's Brave New World

The Good Drug Guide
The Responsible Parent's Guide
To Healthy Mood Boosters For All The Family